Yitan Ning (伊坦宁)伊坦宁
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
批准文号:NMPA approval number: 国药准字H19991398
生产企业Manufacturer
- 成都康弘药业集团股份有限公司Chinese legal name: 成都康弘药业集团股份有限公司
主要成分Active Ingredients
- 特布他林Tebu Talin
药物知识说明
国药准字H19991398是一种在国家药监局注册认定的药品。该药品含有相关活性成分。
该药品关联的活性成分包括：特布他林Tebu Talin。这些成分信息来自国家药监局数据库。
您可以探索含有相同成分的其他药品：特布他林-2d184e41成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 伊坦宁) is a medicine registered with the national drug regulatory authority. It contains active ingredient(s) as recorded.
Active ingredients associated with this product: 特布他林Tebu Talin.
Explore other medicines containing the same ingredient: 特布他林 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 伊坦宁Recorded Chinese name: 伊坦宁
- 剂型Dosage form: 胶囊剂Capsules
- 规格Specification: 1.25mg1.25 mg
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 成都康弘药业集团股份有限公司Chinese legal name: 成都康弘药业集团股份有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H19991398
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H19991398
Manufacturer
Chinese legal name: 成都康弘药业集团股份有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
English translation unavailable. The original Chinese source label remains available below.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H19991398
生产企业
成都康弘药业集团股份有限公司(国产)
适应症
本品用于支气管哮喘，慢性支气管炎，肺气肿和其他肺部疾病引起的支气管痉挛。
用法用量
1.成人，开始1～2周，一次1.25mg，每日2～3次。以后可加至一次2.5mg，每日3次。 2.儿童每日0.065mg/kg，分3次口服。
不良反应
1.偶见震颤、强直性痉挛和心悸，不良反应的程度取决于剂量和给药途径。
2.从小剂量逐渐加至治疗量能减少不良反应。
3.不良反应若出现，大多数在开始用药1～2周内自然消失。
禁忌
对本品过敏者禁用。
注意事项
1.少数病例有手指震颤、头痛、心悸及胃肠障碍。口服5mg时，手指震颤发生率可达20%～33%。
2.甲状腺机能亢进、冠心病、高血压、糖尿病患者慎用。
3.大剂量应用可使有癫痫病史的患者发生酮症酸中毒。
4.长期应用可形成耐药，疗效降低。
贮藏
避光，密闭保存。
规格
1.25mg。
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.